M&A Activity • Dec 16, 2010
M&A Activity
Open in ViewerOpens in native device viewer
News Details
Corporate | 16 December 2010 02:00
A*STAR and Cytos extend Influenza Vaccine Collaboration to Supply of Clinical Trial Material
Cytos Biotechnology AG / Key word(s): Alliance
A*STAR and Cytos extend Influenza Vaccine Collaboration to Supply of Clinical Trial Material
16.12.2010 / 02:00
Cytos Biotechnology will receive fees for the Development, Manufacture and Supply of GMP-grade Influenza Vaccine Candidate
1. Schlieren (Zurich), Switzerland & Singapore, December 16, 2010 – Switzerland's Cytos Biotechnology Ltd (SIX:CYTN) and Singapore's Agency for Science, Technology and Research (A*STAR) jointly announced today the extension of their existing collaboration for the development of a virus-like particle (VLP) based Influenza vaccine. Under this revised agreement, A*STAR will engage Cytos to develop, manufacture, and supply A*STAR with a Good Manufacturing Practice (GMP)-grade investigational vaccine candidate for a human proof-of-concept study in Singapore.
2. This extension follows an earlier Collaborative Research, Development and Commercialisation Agreement, signed by Cytos and A*STAR on 15 th July 2010, to perform research, development and commercialization of a VLP vaccine to manage influenza infections. The objective of this agreement is to establish an independent supply of influenza vaccine for ASEAN and to extend Cytos' R&D pipeline. Cytos holds the worldwide, sub-licensable rights to further develop the vaccine, while A*STAR subsidiaries would earn a royalty on worldwide sales of influenza vaccine products developed under this agreement.
3. Frank Hennecke, PhD, Executive Vice President Product Development at Cytos Biotechnology commented: 'I am very pleased we can contribute our GMP technology and process know-how in the VLP field to this collaboration. Cytos' continuing ability to supply its partners with clinical trial material is a key asset to rapidly move preclinical programs into the clinic.'
4. 'The extension of our collaboration for human proof-of-concept studies is a major step in bringing our research findings from the laboratory to the clinics where they can benefit patients. It also furthers A*STAR's close relationship with our industry partners,' said Prof Alex Matter, Chief Executive Officer of A*STAR's Experimental Therapeutics Centre (ETC). Added Prof Paola Castagnoli, Scientific Director of A*STAR's Singapore Immunology Network (SIgN), 'We are confident that with the combined knowledge base of Singapore's research institutes and the capabilities of industry, we will produce a valuable and cost-effective healthcare solution for Singapore and beyond.'
For further information about the Immunodrug(TM) agreement between A*STAR and Cytos Biotechnology in the Influenza field, see Cytos' and A*STAR's joint press release dated July 15, 2010.
For media queries, please contact:
Cytos Biotechnology Ltd
Wolfgang A. Renner, PhD
Chief Executive Officer
DID: +41 44 733 47 03
Email: [email protected]
Agency for Science, Technology and Research (A*STAR)
Ms Adela Foo
Senior Officer, Corporate Communications
DID: +65 6826 6218
Email: [email protected]
About Cytos Biotechnology
Cytos Biotechnology Ltd is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs(TM). Immunodrugs(TM) are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs(TM) are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its Immunodrug(TM) platform, Cytos Biotechnology has built a diversified pipeline of Immunodrug(TM) candidates in various disease areas, of which five are currently in clinical development. The Immunodrug(TM) candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich, the Company is located in Schlieren (Zurich). Currently, the Company has 81 full-time equivalents. Cytos Biotechnology Ltd is listed on the main segment at the SIX Swiss Exchange (SIX:CYTN).
About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is the lead agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. A*STAR oversees 14 biomedical sciences and physical sciences and engineering research institutes, and nine consortia & centres, located in Biopolis and Fusionopolis as well as their immediate vicinity.
A*STAR supports Singapore's key economic clusters by providing intellectual, human and industrial capital to its partners in industry. It also supports extramural research in the universities, hospitals, research centres, and with other local and international partners.
For more information about A*STAR, please visit www.a-star.edu.sg .
This foregoing press release may contain forward-looking statements that include words or phrases such as 'will', 'can', 'designed', 'intended' or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology Ltd.
End of Corporate News
16.12.2010 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.
EquityStory publishes regulatory releases, media releases on the capital market and press releases.
The EquityStory Group distributes authentic and real-time financial news for over 1’300 listed companies.
The Swiss news archive can be found at http://www.equitystory.ch/nachrichten
| Language: | English |
| Company: | Cytos Biotechnology AG |
| Wagistr. 25 | |
| 8952 Schlieren | |
| Schweiz | |
| Phone: | +41 44 733 4747 |
| Fax: | +41 44 733 4740 |
| E-mail: | [email protected] |
| Internet: | www.cytos.com |
| ISIN: | CH0011025217, CH0029060735 |
| Swiss Security Number: | – |
| Listed: | Regulierter Markt in SIX; Freiverkehr in Berlin, München, Stuttgart; Open Market in Frankfurt |
| End of News | EquityStory AG News-Service |
| - - - |
| 106531 16.12.2010 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.